A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease
Latest Information Update: 03 May 2024
At a glance
- Drugs Ixazomib (Primary)
- Indications Diffuse scleroderma; Interstitial lung diseases; Pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2024 Status changed from recruiting to discontinued due to low enrollment of patients.
- 03 Apr 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Mar 2025.
- 03 Mar 2023 Planned End Date changed from 1 Apr 2024 to 1 Mar 2025.